
    
      Single ascending dose (SAD), multiple ascending dose (MAD), double-blind placebo-controlled
      study in normal human volunteers.

      Secondary objectives:

      To evaluate the pharmacokinetics (PK) of GATE-101 following increasing single and multiple
      doses of intravenously (IV) administered GATE-101.

      GATE-101 or Placebo: Dose/Mode of Administration: Single or 5 Daily Doses;Intravenous
    
  